Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD out side t he Unit ed St at es and Canada, t oday announced new dat a from KEYNOTE-001, a Phase 1b st udy evaluat ing KEYTRUDA ® (pembrolizumab), t he company's ant i-PD-1 t herapy, in naïve and previously-t reat ed pat ient s wit h advanced non-small cell lung cancer (NSCLC). In an analysis of 313 pat ient s from a validat ion dat a set for t umor PD-L1 expression, overall-response rat e (ORR) was 45.2 percent 1 (95% CI, 33.5-57.3) in pat ient s wit h great er t han or equal t o (≥) 50 percent of t umor cells posit ive for PD-L1 expression (n=73). In t he ot her PD-L1 subgroups, ORR was 16.5 percent (95% CI, 9.9-25.1) in pat ient s wit h 1-49 percent t umor cells posit ive (n=103) and 10.7 percent (95% CI, 2.3-28.2) in pat ient s wit h less t han 1 percent t umor cells posit ive (n=28) for PD-L1 expression. In t he t ot al st udy populat ion, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495), which was consist ent wit h dat a previously present ed from t his st udy. These dat a from KEYNOTE-
The efficacy findings demonst rat ed t hat t umor PD-L1 expression may be a relevant biomarker for t he ident ificat ion of NSCLC pat ient s wit h an enhanced likelihood of experiencing improved efficacy wit h an ant i-PD-1 t herapy. PD-L1 is a prot ein t hat may be overexpressed in t he t umor and may cont ribut e mechanist ically t o an inhibit ed immune response.
"In t his st udy, NSCLC pat ient s whose t umors express PD-L1 in t he majorit y of t heir cells experienced t he highest response rat es t o KEYTRUDA t reat ment ," said Dr. Roger Perlmut t er, president , Merck Research Laborat ories. "The result s from t his st udy formed t he basis for our Breakt hrough Therapy designat ion and our recent FDA submission for advanced NSCLC, and indicat e t hat t umor PD-L1 expression may be a relevant biomarker t o ident ify pat ient s more likely t o have higher rat es of response t o KEYTRUDA in t his t umor t ype."
Merck recent ly announced t hat t he company submit t ed a supplement al Biologics License Applicat ion (sBLA) for KEYTRUDA in advanced NSCLC wit h t he U.S. Food and Drug Administ rat ion (FDA). (link) Under PDUFA, t he FDA has 60 days from submission of t he sBLA t o det ermine if t he applicat ion will be accept ed for review. KEYTRUDA was grant ed Breakt hrough Therapy designat ion in advanced NSCLC by t he U.S Food and Drug Administ rat ion (FDA) in Oct ober 2014.
Additio nal Findings fro m KEYNOT E-001 fo r the T o tal Evaluable Po pulatio n
Dat a for progression-free survival (PFS) and overall survival (OS) based on t umor PD-L1 expression was also present ed in 356 naïve and previously-t reat ed pat ient s wit h advanced NSCLC (t ot al evaluable for PD-L1 st aining). In t he ≥50 percent PD-L1 sub-group, median PFS (95% CI) was 6.3 mont hs (2.9-12.5) (n=119); wit hin t his group, PFS was 6.1 mont hs (2.1-12.5) for previously-t reat ed pat ient s (n=294) and 12.5 mont hs (2.4-12.5) for naive pat ient s (n=62). PFS was 3.3 mont hs (95% CI, 2.1-4.1) in t he 1-49 percent PD-L1 sub-group (n=161), and 2.3 mont hs (95% CI, 2.1-4.0) in less t han 1 percent PD-L1 sub-group (n=76). Median OS had not yet been reached in t he ≥50 percent PD-L1 sub-group, regardless of prior t reat ment . Median OS was 8.8 mont hs for t he ot her PD-L1 subgroups (95% CI, 6.8-12.4 for 1-49% sub-group and 5.5-12 for less t han 1% subgroup, respect ively), and was similar regardless of prior t reat ment .
Median durat ion of response was similar across t umor PD-L1 expression subgroups; 12.5 mont hs (2.1+ t o 23.3) 2 for t he ≥50 percent sub-group, 7.2 mont hs (1.4+ t o 8.3+) 3 for t he 1-49 percent sub-group, and not reached (1.0+ t o 10.8+) 4 in t he less t han 1 percent sub-group. At t he t ime of analysis, median follow-up durat ion was 10.9 mont hs (range, 5.2-27.5).
"These result s represent t he largest dat a set of an ant i-PD-1 t herapy in naïve and previously-t reat ed pat ient s wit h advanced non-small cell lung cancer. We are advancing a broad Phase 3 program t hat will furt her charact erize t he pot ent ial benefit of KEYTRUDA compared t o t he st andard of care in t hese pat ient s," said Roger Dansey, t herapeut ic area head and senior vice president , oncology lat e-st age development , Merck Research Laborat ories.
Adverse event s evaluat ed in t he t ot al st udy populat ion were consist ent wit h previously report ed safet y dat a for KEYTRUDA. The most common t reat ment -relat ed adverse event s were fat igue, prurit us, and decreased appet it e. Grade 3-5 t reat mentrelat ed adverse event s occurred in 9.5 percent of pat ient s (n=47). Treat ment -relat ed adverse event s of an inflammat ory or immune-mediat ed nat ure t hat occurred in more t han 2 percent of pat ient s were infusion-relat ed react ions (n=15; 3.0%), hypot hyroidism (n=34; 6.9%), and pneumonit is (n=18; 3.6%). One infusion react ion led t o t reat ment discont inuat ion and all hypot hyroidism cases were successfully managed wit h medical t herapy. There was one t reat ment -relat ed deat h (pneumonit is) and grade 3-5 pneumonit is was observed in 1.8 percent of pat ient s (n=9). At t he t ime of analysis, t wo pneumonit is cases were ongoing (bot h grade 1-2).
Abo ut the KEYNOT E-001 Study and T umo r PD-L1 Validatio n Data Set
KEYNOTE-001 is an ongoing mult i-cent er, single-arm, open-label Phase 1b st udy evaluat ing KEYTRUDA in more t han 1,000 pat ient s wit h diverse lat e-st age cancers -predominant ly lung and melanoma. Three dosing regimens were evaluat ed; 10mg/kg every t wo weeks, 10mg/kg every t hree weeks or 2mg/kg every t hree weeks. The primary endpoint s include ORR and safet y; t he secondary endpoint s include PFS, OS and durat ion of response. Tumor response was assessed every 9 weeks per RECIST 1.1 by independent , cent ral, blinded radiographic review. For t he t umor PD-L1 expression validat ion dat a set , t umor samples were cont emporaneously collect ed wit hin six mont hs of st aining and t umor PD-L1 expression was measured by Dako's immunohist ochemist ry companion diagnost ic t est PD-L1 IHC 22C3 PharmDx. The t raining dat a set for t umor PD-L1 expression from KEYNOTE-001 was present ed at t he AACR Annual Meet ing in April 2014.
Abo ut KEYT RUDA ® (pembro lizumab)
KEYTRUDA (pembrolizumab) is a humanized monoclonal ant ibody t hat blocks t he int eract ion bet ween PD-1 and it s ligands, PD-L1 and PD-L2. By binding t o t he PD-1 recept or and blocking t he int eract ion wit h t he recept or ligands, KEYTRUDA releases t he PD-1 pat hway-mediat ed inhibit ion of t he immune response, including t he ant i-t umor immune response.
KEYTRUDA is indicat ed in t he Unit ed St at es at a dose of 2 mg/kg administ ered as an int ravenous infusion over 30 minut es every t hree weeks for t he t reat ment of pat ient s wit h unresect able or met ast at ic melanoma and disease progression following ipilimumab and, if BRAF V600 mut at ion posit ive, a BRAF inhibit or. This indicat ion is approved under accelerat ed approval based on t umor response rat e and durabilit y of response. An improvement in survival or disease-relat ed sympt oms has not yet been est ablished. Cont inued approval for t his indicat ion may be cont ingent upon verificat ion and descript ion of clinical benefit in t he confirmat ory t rials.
Merck is advancing a broad and fast -growing clinical development program for KEYTRUDA wit h more t han 85 clinical t rialsacross more t han 30 t umor t ypes and more t han 14,000 pat ient s -bot h as a monot herapy and in combinat ion wit h ot her t herapies.
Selected Impo rtant Safety Info rmatio n fo r KEYT RUDA ®
Pneumonit is occurred in 12 (2.9%) of 411 pat ient s wit h advanced melanoma receiving KEYTRUDA (t he approved indicat ion in t he Unit ed St at es), including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) pat ient s, respect ively. Monit or pat ient s for signs and sympt oms of pneumonit is. Evaluat e suspect ed pneumonit is wit h radiographic imaging. Administ er cort icost eroids for Grade 2 or great er pneumonit is. Wit hhold KEYTRUDA for Grade 2; permanent ly discont inue KEYTRUDA for Grade 3 or 4 pneumonit is.
Colit is (including microscopic colit is) occurred in 4 (1%) of 411 pat ient s, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) pat ient s respect ively, receiving KEYTRUDA. Monit or pat ient s for signs and sympt oms of colit is. Administ er cort icost eroids for Grade 2 or great er colit is. Wit hhold KEYTRUDA for Grade 2 or 3; permanent ly discont inue KEYTRUDA for Grade 4 colit is.
Hepat it is (including aut oimmune hepat it is) occurred in 2 (0.5%) of 411 pat ient s, including a Grade 4 case in 1 (0.2%) pat ient , receiving KEYTRUDA. Monit or pat ient s for changes in liver funct ion. Administ er cort icost eroids for Grade 2 or great er hepat it is and, based on severit y of liver enzyme elevat ions, wit hhold or discont inue KEYTRUDA.
Hypophysit is occurred in 2 (0.5%) of 411 pat ient s, including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each) pat ient , receiving KEYTRUDA. Monit or for signs and sympt oms of hypophysit is. Administ er cort icost eroids for Grade 2 or great er hypophysit is. Wit hhold KEYTRUDA for Grade 2; wit hhold or discont inue for Grade 3; and permanent ly discont inue KEYTRUDA for Grade 4 hypophysit is.
Nephrit is occurred in 3 (0.7%) pat ient s receiving KEYTRUDA, consist ing of one case of Grade 2 aut oimmune nephrit is (0.2%) and t wo cases of int erst it ial nephrit is wit h renal failure (0.5%), one Grade 3 and one Grade 4. Monit or pat ient s for changes in renal funct ion. Administ er cort icost eroids for Grade 2 or great er nephrit is. Wit hhold KEYTRUDA for Grade 2; permanent ly discont inue KEYTRUDA for Grade 3 or 4 nephrit is.
Hypert hyroidism occurred in 5 (1.2%) of 411 pat ient s, including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) pat ient s respect ively, receiving KEYTRUDA. Hypot hyroidism occurred in 34 (8.3%) of 411 pat ient s, including a Grade 3 case in 1 (0.2%) pat ient , receiving KEYTRUDA. Thyroid disorders can occur at any t ime during t reat ment . Monit or pat ient s for changes in t hyroid funct ion (at t he st art of t reat ment , periodically during t reat ment , and as indicat ed based on clinical evaluat ion) and for clinical signs and sympt oms of t hyroid disorders. Administ er cort icost eroids for Grade 3 or great er hypert hyroidism. Wit hhold KEYTRUDA for Grade 3; permanent ly discont inue KEYTRUDA for Grade 4 hypert hyroidism. Isolat ed hypot hyroidism may be managed wit h replacement t herapy wit hout t reat ment int errupt ion and wit hout cort icost eroids.
Ot her clinically import ant immune-mediat ed adverse react ions can occur. The following clinically significant , immunemediat ed adverse react ions occurred in less t han 1% of pat ient s t reat ed wit h KEYTRUDA: exfoliat ive dermat it is, uveit is, art hrit is, myosit is, pancreat it is, hemolyt ic anemia, part ial seizures arising in a pat ient wit h inflammat ory foci in brain parenchyma, adrenal insufficiency, myast henic syndrome, opt ic neurit is, and rhabdomyolysis.
For suspect ed immune-mediat ed adverse react ions, ensure adequat e evaluat ion t o confirm et iology or exclude ot her causes. Based on t he severit y of t he adverse react ion, wit hhold KEYTRUDA and administ er cort icost eroids. Upon improvement of t he adverse react ion t o Grade 1 or less, init iat e cort icost eroid t aper and cont inue t o t aper over at least 1 mont h. Rest art KEYTRUDA if t he adverse react ion remains at Grade 1 or less. Permanent ly discont inue KEYTRUDA for any severe or Grade 3 immune-mediat ed adverse react ion t hat recurs and for any life-t hreat ening immune-mediat ed adverse react ion.
Based on it s mechanism of act ion, KEYTRUDA may cause fet al harm when administ ered t o a pregnant woman. If used during pregnancy, or if t he pat ient becomes pregnant during t reat ment , apprise t he pat ient of t he pot ent ial hazard t o a fet us. Advise females of reproduct ive pot ent ial t o use highly effect ive cont racept ion during t reat ment and for 4 mont hs aft er t he last dose of KEYTRUDA.
For t he t reat ment of advanced melanoma, KEYTRUDA was discont inued for adverse react ions in 6% of 89 pat ient s who received t he recommended dose of 2 mg/kg and 9% of 411 pat ient s across all doses st udied. Serious adverse react ions occurred in 36% of pat ient s receiving KEYTRUDA. The most frequent serious adverse drug react ions report ed in 2% or more of pat ient s were renal failure, dyspnea, pneumonia, and cellulit is.
The most common adverse react ions (report ed in ≥20% of pat ient s) were fat igue (47%), cough (30%), nausea (30%), prurit us (30%), rash (29%), decreased appet it e (26%), const ipat ion (21%), art hralgia (20%), and diarrhea (20%).
The recommended dose of KEYTRUDA is 2 mg/kg administ ered as an int ravenous infusion over 30 minut es every t hree weeks unt il disease progression or unaccept able t oxicit y. No formal pharmacokinet ic drug int eract ion st udies have been conduct ed wit h KEYTRUDA. It is not known whet her KEYTRUDA is excret ed in human milk. Because many drugs are excret ed in human milk, inst ruct women t o discont inue nursing during t reat ment wit h KEYTRUDA. Safet y and effect iveness of KEYTRUDA have not been est ablished in pediat ric pat ient s.
Abo ut Lung Cancer
Lung cancer, which forms in t he t issues of t he lungs, usually wit hin cells lining t he air passages, is t he leading cause of cancer deat h worldwide. Each year, more people die of lung cancer t han die of colon, breast , and prost at e cancers combined. The t wo main t ypes of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is t he most common t ype of lung cancer, account ing for about 85 percent of all cases. The five-year relat ive survival rat e for all advanced or met ast at ic (St age IV) lung cancers combined is est imat ed t o be four percent .
Abo ut PD-L1 and PD-L1 Expressio n
PD-L1, also called programmed deat h-ligand 1, is a prot ein expressed on many t ypes of cells, including some cancer cells. Under normal condit ions, t he int eract ion of PD-L1 wit h anot her prot ein, called programmed deat h recept or-1 (PD-1), serves as an import ant immune syst em checkpoint , keeping t he immune syst em in balance and prevent ing t he body from at t acking it s own cells when inflammat ion or an infect ion is present . When cancerous t umors express PD-L1, however, t hey are able t o escape det ect ion and dest ruct ion by cyt ot oxic T-cells -a t ype of cancer-killing immune cell -allowing t he t umor t o survive and grow. Tumor PD-L1 expression has been observed at varying levels across many t umor t ypes, including breast , lung and bladder cancer. High levels of PD-L1 expression, called overexpression, are under invest igat ion for pot ent ial use as a way t o help ident ify pat ient s wit h an enhanced likelihood t o respond t o cert ain immune-based t reat ment approaches.
Our Fo cus o n Cancer
Our goal is t o t ranslat e breakt hrough science int o biomedical innovat ions t o help people wit h cancer worldwide. For Merck Oncology, helping people fight cancer is our passion, support ing accessibilit y t o our cancer medicines is our commit ment , and pursuing research in immuno-oncology is our focus t o pot ent ially bring new hope t o people wit h cancer. For more informat ion about our oncology clinical t rials, visit www.merck.com/clinicalt rials.
Abo ut Merck
Today's Merck is a global healt hcare leader working t o help t he world be well. Merck is known as MSD out side t he Unit ed St at es and Canada. Through our prescript ion medicines, vaccines, biologic t herapies and animal healt h product s, we work wit h cust omers and operat e in more t han 140 count ries t o deliver innovat ive healt h solut ions. We also demonst rat e our commit ment t o increasing access t o healt hcare t hrough far-reaching policies, programs and part nerships. For more informat ion, visit www.merck.com and connect wit h us on Twit t er, Facebook and YouTube.
Fo rward-Lo o king Statement
This news release includes "forward-looking st at ement s" wit hin t he meaning of t he safe harbor provisions of t he Unit ed St at es Privat e Securit ies Lit igat ion Reform Act of 1995. These st at ement s are based upon t he current beliefs and expect at ions of Merck's management and are subject t o significant risks and uncert aint ies. There can be no guarant ees wit h respect t o pipeline product s t hat t he product s will receive t he necessary regulat ory approvals or t hat t hey will prove t o be commercially successful. If underlying assumpt ions prove inaccurat e or risks or uncert aint ies mat erialize, act ual result s may differ mat erially from t hose set fort h in t he forward-looking st at ement s.
Risks and uncert aint ies include, but are not limit ed t o, general indust ry condit ions and compet it ion; general economic fact ors, including int erest rat e and currency exchange rat e fluct uat ions; t he impact of pharmaceut ical indust ry regulat ion and healt hcare legislat ion in t he Unit ed St at es and int ernat ionally; global t rends t oward healt hcare cost cont ainment ; t echnological advances, new product s and pat ent s at t ained by compet it ors; challenges inherent in new product development , including obt aining regulat ory approval; Merck's abilit y t o accurat ely predict fut ure market condit ions; manufact uring difficult ies or delays; financial inst abilit y of int ernat ional economies and sovereign risk; dependence on t he effect iveness of Merck's pat ent s and ot her prot ect ions for innovat ive product s; and t he exposure t o lit igat ion, including pat ent lit igat ion, and/or regulat ory act ions.
Merck undert akes no obligat ion t o publicly updat e any forward-looking st at ement , whet her as a result of new informat ion, Ticker: MRK Exchange: NYSE fut ure event s or ot herwise. Addit ional fact ors t hat could cause result s t o differ mat erially from t hose described in t he forward-looking st at ement s can be found in Merck's 2014 Annual Report on Form 10-K and t he company's ot her filings wit h t he Securit ies and Exchange Commission (SEC) available at t he SEC's Int ernet sit e (www.sec.gov). 
